Enzyme Replacement Therapy Market Poised for Strong Growth, Projected to Reach USD 20,289.1 Million by 2034 at a 6.60% of CAGR

Posted on 2024-11-18 by Future Market Insights in Healthcare, Pharmaceuticals // 0 Comments

Enzyme Replacement Therapy Market

The Global Enzyme Replacement Therapy (ERT) Market is on track for significant growth, with a projected market valuation of USD 10,707.6 million by 2024. This growth is driven by the increasing prevalence of lysosomal storage diseases (LSDs), such as Gaucher and Fabry diseases, and the growing adoption of ERT for their treatment. The market is anticipated to expand at a healthy compound annual growth rate (CAGR) of 6.60% from 2024 to 2034.

ERT is also used in the treatment of various rare diseases such as Gaucher disease and Fabry disease. Advancements in medicare technology and the proliferation of modern and sophisticated facilities in healthcare organizations, both public as well as private, have further led to the expansion of this market. The industry is anticipated to grow at a healthy CAGR of 6.60% from 2024 to 2034.

Government initiatives to make people more aware and lenient reimbursement policies are also responsible for the growth of the market. The market is slated to reach a valuation of US$ 20,289.1 million by the end of 2034.

However, increased costs and unavailability of skilled workforce and healthcare facilities are hindering market growth in some parts of the world. Coupled with a lack of awareness and concerns regarding the efficacy of these treatments, the market has definite obstacles to face in the forecast period.

Key Market Drivers
Lysosomal storage diseases, which affect one in every seven thousand childbirths, are on the rise, particularly in underdeveloped regions with limited access to advanced medical care and awareness. This growing incidence of LSDs has created a strong demand for enzyme replacement therapies, which are critical for managing the symptoms and progression of these rare diseases.

The rapid advancements in healthcare technology, coupled with the increasing availability of sophisticated healthcare facilities both in public and private sectors, are expected to fuel market growth. ERT’s effectiveness in treating several rare conditions, including Gaucher and Fabry diseases, has further contributed to its widespread adoption.

Key Takeaways

Market Valuation in 2024: USD 10,707.6 million
CAGR: 6.60% from 2024 to 2034
Market Drivers: Rising prevalence of lysosomal storage diseases, advancements in healthcare facilities, and increased adoption of ERT for the treatment of rare diseases.

Regional Insights

North America: Dominates the market, owing to well-established healthcare infrastructure, high awareness of rare diseases, and the availability of advanced medical therapies.
Europe: Significant growth, driven by supportive healthcare policies, improved access to healthcare services, and increasing investments in rare disease treatments.
Asia-Pacific: The region is expected to experience rapid growth, especially in countries like India and China, where awareness is rising, and healthcare accessibility is improving.
Latin America & Middle East/Africa: Gradual growth, as these regions face an increasing burden of rare diseases and are improving healthcare infrastructure to address these challenges.

Competitive Landscape

The enzyme replacement therapy market is a very limited one as the disease mortality rate is minuscule. This is why very few companies exist in the market, most of which have already established themselves as key players.

The competition is also not that intense as top players hold the majority share of the market. Besides this, these companies are found collaborating with research institutions for more effective and affordable therapies.

Recent Developments in the Enzyme Replacement Therapy Market

In February 2024, Sanofi unveiled positive outcomes for its enzyme replacement therapy, avalglucosidase alfa, for Pompe disease.
In February 2024, the first trial for a gene therapy treating Hunter syndrome was launched in Manchester, United Kingdom, aiming to replace weekly enzyme therapy. Led by Professor Brian Bigger, the research follows successful trials in mice, offering hope for young patients.
In January 2024, the USA FDA designated JR-441, an enzyme replacement therapy by JCR Pharmaceuticals, as an orphan drug for Sanfilippo syndrome type A. It received incentives for clinical development and review, aiming to aid its progress.
In February 2024, BioMarin Pharma received a DOJ subpoena on sponsored testing programs for two therapies. The company disclosed it had provided documents and was cooperating but acknowledged uncertainty about compliance with laws.
In November 2023, the FDA approved Takeda’s enzyme replacement therapy for a rare blood disorder. It marked a significant milestone, offering hope for patients facing life-threatening conditions and highlighting advancements in medical treatment.
In November 2023, AstraZeneca’s rare disease unit received a NICE recommendation for its enzyme replacement therapy for Wolman disease in infants. This marked the first NHS-available treatment for the rare genetic condition, impacting around one in 350,000 births.
In August 2023, Amicus Therapeutics launched Pombiliti for late-onset Pompe disease in the UK. The therapy, a combination of cipaglucosidase alfa and miglustat, received approval from the MHRA. It aimed to address symptoms and improve patient’s quality of life.

A Full Report Overview

Key Companies

Sanofi Genzyme
Shire (now part of Takeda Pharmaceuticals)
BioMarin Pharmaceutical Inc.
Amicus Therapeutics
Alexion Pharmaceuticals
Ultragenyx Pharmaceutical Inc.
Sarepta Therapeutics
Biomarin
Genzyme (now part of Sanofi)
Takeda Pharmaceuticals
Pfizer Inc.
AbbVie Inc.
Vertex Pharmaceuticals
Sangamo Therapeutics
Regeneron Pharmaceuticals Inc.
Spark Therapeutics (now part of Roche)
Orchard Therapeutics
Novartis AG
CSL Behring
Audentes Therapeutics

Key Segments of the Enzyme Replacement Therapy Market

By Therapeutic Conditions:

Enzyme Replacement Therapy for Fabry Disease
Enzyme Replacement Therapy for Gaucher Disease
Enzyme Replacement Therapy for Mucopolysaccharidosis (MPS):
- MPS I (Hurler Syndrome)
- MPS II (Hunter Syndrome)
- MPS IVA (Morquio Syndrome, Type A)
- MPS VI (Maroteaux-Lamy Syndrome)
- MPS VII (Sly Syndrome)
Enzyme Replacement Therapy for Pompe Disease
Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
Others

By Route of Administration:

Oral Enzyme Replacement Therapy
Injectable Enzyme Replacement Therapy

By Distribution Channel:

Hospital Pharmacies
Specialty Treatment Pharmacies
Retail Pharmacies

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East and Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Matched content

Editor’s pick